在健康个体的优糖设置中考虑基础胰岛素制剂的药学动力学变异的因素
Hui Liu1,2, Ting Li3, Hongling Yu1
1Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Guoxue Lane No.37, Wuhou District, Chengdu, Sichuan, China.
Clinical pharmacokinetics
|December 1, 2025
概括
目标血糖水平的变化可能会解释与参考产品相比,胰岛素生物类似剂的药理学效应的差异. 这一发现对于理解胰岛素生物类似药的疗效至关重要.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 生物模拟研究的研究.
背景情况:
- 欧糖技术是比较胰岛素药理动力学 (PK) 和药理动力学 (PD) 的标准.
- 胰岛素生物类似药和参考产品之间的PD概况可能存在差异,尽管它们具有相似的PK.
- 这项研究研究了导致观察到PD变化的因素.
研究的目的:
- 为了确定影响胰岛素生物类似药物的药理动力学变异性的因素.
- 为了比较胰岛素降解剂生物类似剂 (BioIDeg) 和其参考产品 (Tresiba) 的PK/PD概况.
主要方法:
- 分析了比较BioIDeg和Tresiba的euglycemic研究的数据.
- 根据曲线下的葡萄糖输注速率 (GIR) 面积的比率,将受试者分为几组.
- 使用后勤回归来确定影响变化的重要因素.
主要成果:
- 分析包括了58名健康受试者.
- 在两组之间观察到目标血糖,基底C和胰岛素AUC的显著差异.
- 目标血糖的变化被确定为导致PD变化的独立因素.
结论:
- 目标血糖的变化可能会导致长效胰岛素制剂的药理动力学变化.
- 了解这些变异对于在临床环境中准确评估胰岛素仿生药非常重要.
相关概念视频
Dosage Regimen: Individualization
146
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
146
Insulin: Dosing Regimen and Adverse Effects
644
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
644
Dosage Regimens: Partial Pharmacokinetic Parameters
132
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
132
Two-Compartment Open Model: IV Bolus Administration
1.0K
The two-compartment model for intravenous (IV) bolus administration illustrates drug distribution in the body, subdividing it into central and peripheral compartments. This model operates on the concept of two-compartment kinetics. The drug's plasma concentration shows a bi-exponential decline following IV bolus administration, signaling the presence of two disposition processes: distribution and elimination.
The disparity between drug input and the sum of drug transfer rates between...
The disparity between drug input and the sum of drug transfer rates between...
1.0K
Factors Affecting Protein-Drug Binding: Patient-Related Factors
275
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
275
One-Compartment Open Model for IV Bolus Administration: Estimation of Elimination Rate Constant, Half-Life and Volume of Distribution
798
The one-compartment open model is a simplified approach used in pharmacokinetics to understand the distribution and elimination of a drug administered through an intravenous bolus. This model assumes rapid drug dispersal throughout the body and elimination using a first-order process. Key pharmacokinetic parameters, such as the elimination rate constant (k), half-life (t1/2), and the apparent volume of distribution (Vd), can be estimated from this model. The elimination rate is calculated...
798


